I just thought I would rehash the phase 2 trial results and the relevance to the phase 3 trial.
The phase 2 trial post-hoc analysis of the composite endpoint developed with the FDA of "at least a 50% improvement in low back pain, 15 point improvement in ODI and no treatment intervention (surgical or injection)" found:
- 44.4% of the 6m MPC group met the endpoint at 6 and 12 months (p=<0.05)
- 37% of the MPC 6m group met the endpoint at 12 and 24 months (p=0.09)
- Compared with 11.8% of the saline/placebo group at both 6-12 and 12-24 months
The phase 3 trial uses the 6m MPC dose as this was found to be most effective in the phase 2 trial and importantly the primary endpoint is this exact composite endpoint developed with the FDA over a timeframe of 24 months.
This means that if the 6m MPC group has any % higher than the placebo group even if it isn't as strong as the results above it will successfully meet the primary endpoint.
Ideally, we would want the phase 2 results repeated or even stronger results.
- Forums
- ASX - By Stock
- MSB
- MPC-06-ID Phase 3 results countdown
MPC-06-ID Phase 3 results countdown, page-186
-
- There are more pages in this discussion • 88 more messages in this thread...
You’re viewing a single post only. To view the entire thread just sign in or Join Now (FREE)
Featured News
Add MSB (ASX) to my watchlist
(20min delay)
|
|||||
Last
$1.13 |
Change
0.035(3.21%) |
Mkt cap ! $1.284B |
Open | High | Low | Value | Volume |
$1.09 | $1.13 | $1.07 | $3.910M | 3.535M |
Buyers (Bids)
No. | Vol. | Price($) |
---|---|---|
2 | 27197 | $1.11 |
Sellers (Offers)
Price($) | Vol. | No. |
---|---|---|
$1.13 | 43578 | 3 |
View Market Depth
No. | Vol. | Price($) |
---|---|---|
4 | 31763 | 1.100 |
2 | 33264 | 1.090 |
2 | 18897 | 1.085 |
2 | 18926 | 1.080 |
1 | 18000 | 1.075 |
Price($) | Vol. | No. |
---|---|---|
1.130 | 23400 | 3 |
1.135 | 1090 | 1 |
1.140 | 65000 | 4 |
1.145 | 64500 | 3 |
1.150 | 92314 | 9 |
Last trade - 16.10pm 27/09/2024 (20 minute delay) ? |
Featured News
MSB (ASX) Chart |